Literature DB >> 20587945

Endothelin-1 regulates rat bone sialoprotein gene transcription.

Xinyue Li1, Zhitao Wang, Li Yang, Zhengyang Li, Yorimasa Ogata.   

Abstract

Endothelin-1 (ET-1) was originally discovered as a vasoconstrictor protein excreted by vascular endothelial cells. Recently, tumor-produced ET-1 has been considered to stimulate osteoblasts to form new bone, and to be an important mediator of osteoblastic bone metastasis. ET-1 has high affinity for two different membrane receptors, ET(A)R and ET(B)R, which are expressed by many types of cells including osteoblasts. Bone sialoprotein (BSP) is a phosphorylated and sulfated glycoprotein associated with mineralized connective tissues. To investigate the effects of ET-1 on BSP transcription, we used rat osteoblast-like ROS17/2.8 cells. Levels of BSP and osteopontin mRNA were increased at 12 h after treatment with ET-1 (10 ng/ml), and ET-1 at the same concentration induced luciferase activity of a -116 to +60 BSP promoter construct at 6 h. Transcriptional activity of -84BSPLUC, which contains the cAMP response element (CRE), was increased by ET-1. Furthermore, at 6 h, ET-1 (10 ng/ml) increased the binding of nuclear protein to CRE, the FGF2 response element (FRE) and the homeodomain protein-binding site (HOX). Antibodies against CREB1, JunD and Fra2 disrupted the formation of CRE-protein complexes, while antibodies against Runx2 and Dlx5 reduced the formation of FRE- and HOX-protein complexes. These findings indicate that ET-1 increases BSP transcription via the CRE, FRE and HOX sites in the rat BSP gene promoter.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20587945     DOI: 10.2334/josnusd.52.221

Source DB:  PubMed          Journal:  J Oral Sci        ISSN: 1343-4934            Impact factor:   1.556


  1 in total

1.  Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma.

Authors:  Javier Muñoz-Garcia; Jorge William Vargas-Franco; Bénédicte Brounais-Le Royer; Denis Cochonneau; Jérôme Amiaud; Marie-Françoise Heymann; Dominique Heymann; Frédéric Lézot
Journal:  Cancers (Basel)       Date:  2022-03-30       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.